Acta Dermato Venereologica · 2001 · 57 citations · 5 references
Veterinary MedicineImmunologyPharmacotherapyCell AdhesionImmunopathologyInflammationAngiogenesisEndothelial ActivationEndothelial DysfunctionInflammatory MediatorsLeukocyte AdhesionSystemic SclerosisCellular Adhesion MoleculesCytokine-mediated Vascular ResponsesEndothelial Adhesion MoleculesIntercellular Adhesion Molecule 1Prostacyclin AnalogsScleroderma TreatmentVascular Cell Adhesion Molecule 1Vascular Endothelial Growth Factor
Microvascular damage occurs in systemic sclerosis and is associated with increased serum levels of endothelial adhesion molecules and endothelium-associated cytokines, including vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), E-selectin, endothelin-1 and vascular endothelial growth factor (VEGF). Iloprost, a prostacyclin analogue, induces clinical benefit in patients suffering from scleroderma-related Raynaud's phenomenon. This study was performed to investigate the effect of iloprost infusions on endothelium activation. Serum samples from 12 patients with systemic sclerosis were examined using specific enzyme-linked immunoassays. The serum levels of sICAM-1, sVCAM-1 and soluble E-selectin were initially elevated and significantly reduced after iloprost infusions. The serum concentrations of VEGF and endothelin-1 revealed decreased levels after therapy too. These results indicate that the well-known clinical benefit of iloprost infusions on Raynaud's phenomenon is serologically detectable by a reduction of serum levels of endothelium-associated adhesion molecules, cytokines and growth factors reflecting an improvement in endothelial function.
5
Timothy M. Carlos, Nicholas L. Kovach, Barbara R. Schwartz et al. · Blood · 1991 · 317 citations
Matthias S. Gruschwitz, O. P. Hornstein, Peter Von Den Driesch · Arthritis & Rheumatism · 1995 · 138 citations